Investigation of multi-drug resistance 1 (MDR1) and cytochrome P4502C8 (CYP2C8) pharmacogenetics on outcome from treatment of advanced breast cancer using paclitaxel in a UK national trial of a weekly versus 3-weekly schedule.

Dr Johanne Lee; Julieann Sludden; Professor Alan Boddy; Dr Mark Verrill

Investigation of multi-drug resistance 1 (MDR1) and cytochrome P4502C8 (CYP2C8) pharmacogenetics on outcome from treatment of advanced breast cancer using paclitaxel in a UK national trial of a weekly versus 3-weekly schedule. Lookup NU author(s) Dr Johanne Lee Julieann Sludden Professor Alan Boddy Dr Mark Verrill



Author(s)		Lee, J. S., Sludden, J., Ferrigan, L. M., Boddy, A. V., Verrill, M. W., Cameron, D.
Editor(s)
Publication type		Conference Proceedings (inc. Abstract)
Conference Name		29th Annual San Antonio Breast Symposium
Conference Location		San Antonio, Texas, USA
Year of Conference		2006
Date		14/17-12-2006
Volume		100
Number of Volumes		1
Pages		S252 no. 5118
Sponsor(s)		San Antonio Cancer Institute, Baylor College of Medicine, Cancer Therapy and Research Center, The University of Texas
		0167-6806
ISBN




Full text for this publication is not currently held within this repository. Alternative links are provided below where available.



Publisher		Breast Cancer Research and Treatment, Springer Netherlands
URL		http://dx.doi.org/10.1007/s10549-006-5678-0
DOI		10.1007/s10549-006-5678-0

Actions
Library holdings		Search Newcastle University Library for this item